NanoViricides, Inc. presented a corporate update on its broad-spectrum antiviral drug candidate, NV-387, at the Spartan Capital Investors Conference on November 4, 2024. Anil R. Diwan, Ph.D., President and Executive Chairman of NanoViricides, highlighted NV-387's potential to revolutionize antiviral treatments, addressing a $2.5 to $4.3 billion market for RSV alone.
NV-387: A Broad-Spectrum Antiviral Candidate
NV-387, enabled by NanoViricides' nanoviricides technology platform, has completed Phase I clinical trials. Preclinical studies have demonstrated strong antiviral activity against a range of viral diseases, including Influenza, RSV, COVID-19, and MPox in animal models, showing superiority compared to existing treatments.
Market Opportunity
The company anticipates a market size exceeding $10 billion by 2027 for the indications targeted by NV-387. This includes RSV, COVID-19, Influenza, and MPOX/Smallpox infections.
NanoViricides' Pipeline and Technology
NanoViricides is a clinical-stage company focused on developing nanomedicines for antiviral therapy. Their lead drug candidate, NV-387, is being developed for RSV, COVID, Long COVID, Influenza, and MPOX/Smallpox infections. The company is also advancing NV-HHV-1 for the treatment of Shingles.
NanoViricides' technology is based on a license from TheraCour Pharma, Inc., utilizing special-purpose nanomaterials for antiviral applications. The company's pipeline includes drug candidates targeting oral and genital Herpes, viral diseases of the eye, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus.
Development Strategy
NanoViricides is currently focused on advancing NV-387 into Phase II human clinical trials. The company is also developing NV-CoV-2 and NV-CoV-2-R as drug candidates for COVID-19, with NV-CoV-2-R encapsulating remdesivir within polymeric micelles.
